-
Biosimilar's Role in Improving Patient Access
- 2024/02/27
- 再生時間： 43 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Biosimilars are entering the market at their fastest pace ever. In this episode, we interview a renowned health economist and an expert consultant in biosimilar distribution and patient support to explore the complex landscape of biosimilars, including examining the hurdles and breakthroughs in achieving acceptance by payers and providers and how best to improve patient access and affordability in a market dominated by established brands.
Dr. Jason Shafrin, Senior Managing Director, Center for Healthcare Economics and Policy at FTI Consulting
Marina Allen, SVP, Fingerpaint Market Access, Patient Support & Access Strategy Leader in Pharma-Biotech
Biosimilars
The Biologics Price Competition and Innovation Act of 2009
PBMs (Pharmacy Benefit Managers)
Medicare Advantage
Humira (biosimilars)
340B program
Inflation Reduction Act
Medicare Part D
"brown bagging and white bagging"
Mark Cuban (CostPlusDrugs)
GoodRx
average sales price (ASP)
electronic health record (EHR) system
Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.